Nouvelle déclaration d'incident
No de la demande: 2026-3708
Numéro de référence du titulaire d'homologation: 2026-US-008186
Nom du titulaire (nom légal complet, aucune abbréviation): The Hartz Mountain Corporation
Adresse: 200 Plaza Drive, Suite 402
Ville: Secaucus
État: New Jersey
Pays: USA
Code postal /Zip: 07094
Incident chez un animal domestique
Pays: UNITED STATES
État: MISSOURI
ARLA No d'homologation ARLA No de la demande d'homologation EPA No d'homologation. 2596-83
Nom du produit: Hartz UltraGuard Flea and Tick Collar for Cats and Kittens
Autre (préciser)
CollarOui
Autres unités: Collar
Site: Animal / Usage sur un animal domestique
Propriétaire de l'animal
Cat / Chat
Domestic Longhair
1
Homme
2.0
9
lbs
Cutanée
>24 hrs <=3 days / >24 h <=3 jours
>24 hrs <=3 days / >24 h <=3 jours
Système
>1 wk <=1 mo / > 1 sem < = 1 mois
Inconnu
Inconnu
Mort
Treatment / Traitement
(p.ex. description des symptômes tels que la fréquence et la gravité
On approximately 06-Apr-2026, a 2 year old, 9 pound, neutered, male, Domestic Longhair cat, in unknown condition, with no known concomitant medical conditions, had 1 collar of Hartz UltraGuard Flea and Tick Collar for Cats and Kittens - Purple (Tetrachlorvinphos (Rabon)) placed around the neck by the animal owner. On approximately 09-Apr-2026, the cat develop lethargy and weakness. The animal owner removed the collar. On 16-Apr-2026, the cat developed yellowing of the skin and gums (jaundice). The animal owner brought the cat to a veterinarian for evaluation where the cat was diagnosed with unspecified liver failure. Unknown if or what treatments or diagnostics were performed. On 20-Apr-2026, the cat died at home. No further information is expected.
Mort
Assessment: This product contains tetrachlorvinphos, an organophosphate insecticide, that is considered to have a good margin of safety in cats. The active ingredient is poorly absorbed across intact skin. If product residue were ingested only mild GI upset would be expected. Severe systemic signs including liver failure progressing to death are not expected. Other causes including underlying metabolic disease, infectious disease, cholangiohepatitis, and toxin exposure (acetaminophen) should also be considered. Without a necropsy, the cause of death remains unknown and the relationship to product use is inconclusive. The information contained in this report is based on self-reported statements provided to the registrant during telephone interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and cannot form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews.